Answers are grounded in this paper and cite their sources.
Nonsmall cell lung cancer (NSCLC) remains a leading malignancy with limited therapies, calling for natural product-derived anticancer candidates with well-defined mechanisms. In this study, Periplocymarin was identified as a selective anti-NSCLC candidate. Its antitumor activity was verified in cell proliferation, apoptosis, migration assays and patient-derived organoid models. To dissect its antitumor mechanism, we employed an integrated strategy combining transcriptome sequencing, network pharmacology, thermal proteome profiling (TPP), microscale thermophoresis (MST) and molecular simulations, and validated the involvement of p38α MAPK (MAPK14) phosphorylation via Western blot. Finally, the in vivo antitumor efficacy and safety of Periplocymarin were validated using nude mouse xenograft and patient-derived xenograft (PDX) models. Periplocymarin inhibited proliferation and migration and induced apoptosis in NSCLC cells in a concentration-dependent manner, while also suppressing Patient-Derived Organoid (PDO) growth. Integrated analyses and experimental validation indicated MAPK14 as a candidate target associated with Periplocymarin treatment. Periplocymarin reduced MAPK14 phosphorylation, and MAPK14 knockdown partially attenuated its antitumor effects. In vivo, Periplocymarin significantly suppressed tumor growth in nude mouse subcutaneous xenograft and PDX models, with decreased Ki-67 and phospho-MAPK14 levels and no evident toxicity. This study demonstrates Periplocymarin exerts anti-NSCLC activity via modulating MAPK14 phosphorylation, supporting its further development for NSCLC therapy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: